In morning trade the Cann Group Ltd (ASX: CAN) share price is rocketing higher.
At the time of writing the cannabis company’s shares are up 20% to 51 cents.
Why is the Cann Group share price rocketing higher?
Investors have been buying Cann Group’s shares after it released an update on the medicinal cannabis products it is manufacturing with IDT Australia Limited (ASX: IDT).
According to the release, the first commercial medicinal cannabis product from its Australian-based cultivation operations has been packed by IDT Australia under cGMP conditions.
It will now undergo stability testing ahead of release in the first quarter of 2020.
What is Cann Group producing?
Cann Group is packing medicinal cannabis dried flower into 10g bottles in IDT Australia’s licensed cGMP manufacturing facilities.
This product will be made available to Australian patients early in 2020, who can access the product under the Special Access Scheme (SAS).
Cann Group has a national distribution arrangement with Symbion Health, which will ensure product is available via Symbion’s extensive network of retail and hospital pharmacies.
The first commercial product will initially be utilised for Australian domestic requirements, but Cann Group has its eyes on international markets.
It notes that it recently completed its first export of Australian grown and packaged medicinal cannabis dry flower to Aurora Cannabis in Canada. Whilst this is strictly for research purposes, management feels it is an important validation of export pathways ahead of future commercial supply.
Cann Group CEO, Peter Crock, believes this represents a significant milestone in the commercialisation phase of the business.
He said: “IDT has demonstrated a clear capability to manufacture cGMP medicinal cannabis products. As Cann Group increases our cultivation and production capacity at the new Mildura facility, it is critical that we have the ability to efficiently convert that material into commercial formulations.”
Things certainly are heating up in the industry. Earlier this week AusCann Group Holdings Ltd (ASX: AC8) announced the impending release of its first cannabis products.
The post Why this ASX cannabis share is rocketing 20% higher today appeared first on Motley Fool Australia.
While these are positive developments, I would sooner buy these exciting growth shares than Cann Group or AusCann.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019